Fact Sheet: Cancer Drug Prices

THE PROBLEM: A CRISIS OF AFFORDABILITY The out-of-control prices set by Big Pharma on prescription drugs used to treat cancer have created a crisis of affordability — and placed breakthrough treatments out-of-reach for too many American patients. Patients and families should never have to face heart-wrenching choices between paying for their cancer treatment or…

Drug Pricing Overview – 117th Congress

Fact Sheet: OUT-OF-CONTROL DRUG PRICES AN URGENT CONCERN FOR AMERICAN FAMILIES

Ninety-six percent of voters agree lowering drug prices is an important challenge facing Americans. Seventy-one percent say lowering drug prices is “very important.”

Fact Sheet: Patent Abuse

Prescription drug prices are out-of-control thanks to the anti-competitive tactics and price-gouging practices of Big Pharma. Despite an escalating crisis of affordability, made worse by the economic impact of the COVID-19 pandemic, brand name drug companies continue to engage in anti-competitive behavior and price-gouging tactics in order to keep prices high and pad their…

Fact Sheet: Oversight Hearings

AN OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE The U.S. House of Representatives Committee on Oversight and Reform is scheduled to hold two days of hearings with Big Pharma executives on September 30 and October 1. Executives for brand name drug giants including Bristol Myers Squibb/Celgene, Amgen and Novartis are slated to testify. Lawmakers must…

Fact Sheet: No Price Hikes

Prescription drug prices are out-of-control. Too many Americans were already unable to afford their medications and resorting to dangerous measures like rationing — before the historic economic uncertainty of the current crisis. It is critical patients are able to take their medications as prescribed in order to stay healthy. Now is not the time…

Fact Sheet: KEEP YOUR PROMISE: CONGRESS MUST ACT TO HOLD BIG PHARMA ACCOUNTABLE, LOWER DRUG PRICES

THE CRISIS OF RISING PRESCRIPTION DRUG PRICES: The anti-competitive tactics and price-gouging practices of Big Pharma have created a crisis of prescription drug affordability in America. Today, as many as one-in-four Americans are unable to afford their medications. Despite the mounting crisis, brand name drug makers continue increasing prices and fighting to evade responsibility.

Document: CSRxP Letter to Senate Finance Committee

The Campaign for Sustainable Rx Pricing (CSRxP) wishes to commend you for your strong bipartisan efforts to lower prescription drug prices for Americans by moving forward with the U.S. Senate Committee on Finance package on drug pricing. CSRxP believes that the Senate Finance package is a good first step in slowing the unsustainable growth…

Document: Restructuring the CMS Federal Reinsurance Program to Include Manufacturer Liability

As prescription drug prices continue to rise, many stakeholders have debated how to slow the trend and who should pay for it. The Medicare Advantage and Part D programs remain at the center of this discussion. Organizations such as the Medicare Payment Advisory Commission (“MedPAC”) and the American Action Form (“AAF”) as well as…

Document: USMCA Letter

The Campaign for Sustainable Rx Pricing (CSRxP) is a broad-based coalition of leaders – physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists and businesses — promoting bipartisan, market-based solutions to lower drug prices in America. We appreciate the bipartisan attention and activity that lawmakers in Congress have placed on tackling the crisis of rising…